Fig. 5

BCL-6 recruits EZH2 and HDAC5, which bind to the miR-142 promoter. a Coimmunoprecipitation using anti-BCL-6 in SLE CD4⁺ T cells and the detection of BCL-6 and EZH2/HDAC5 by western blotting. b ChIP-qPCR analysis of the enrichment of EZH2 and HDAC5 bound to the miR-142 promoter in chromatin fractions extracted from normal CD4⁺ T cells transfected with BCL-6 expression plasmid or a negative control. The results are presented relative to those obtained with input DNA prepared from untreated chromatin. Data represent the mean of three independent experiments. c ChIP-qPCR analysis of the enrichment of EZH2 and HDAC5 bound to the miR-142 promoter in chromatin fractions extracted from normal CD4⁺ T cells transfected with EZH2/HDAC5 expression plasmid and BCL-6 interference plasmid. Data represent the mean of three independent experiments. d Real-time PCR analysis of the expression levels of miR-142-3p/5p in normal CD4⁺ T cells transfected with EZH2/HDAC5 expression plasmid and BCL-6 interference plasmid. Data represent the mean of three independent experiments. e Real-time PCR analysis of the expression levels of miR-142-3p/5p in normal CD4⁺ T cells transfected with EZH2/HDAC5 interference plasmid. Data represent the mean of three independent experiments. f ChIP-qPCR analysis of the enrichment of EZH2 and HDAC5 bound to the miR-142 promoter in chromatin fractions extracted from normal (n = 12) and SLE (n = 12) CD4⁺ T cells. g ChIP-qPCR analysis of the enrichment of EZH2 and HDAC5 bound to the miR-142 promoter in chromatin fractions extracted from SLE CD4⁺ T cells transfected with BCL-6 interference plasmid or negative control. Data represent the mean of three independent experiments (*P < 0.05, **P < 0.01)